Monopar Therapeutics (MNPR) vs Wave Life Sciences (WVE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Monopar Therapeutics (MNPR) has outperformed Wave Life Sciences (WVE) over the past year, losing 24.6% versus a loss of 63.7%. Over five years, MNPR leads with a +184.5% price change compared with -35.8% for WVE. Wave Life Sciences is the larger company by market cap ($504.9 million vs $467.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNPR | WVE |
|---|---|---|
| Share price | $69.00 | $2.56 |
| Market cap | $467.60M | $504.91M |
| 1-day change | -1.84% | -5.88% |
| YTD return | +5.67% | -84.94% |
| 1-year return | -24.64% | -63.69% |
| 5-year return | +184.54% | -35.84% |
| EPS (TTM) | $-2.44 | $-1.07 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $42.73M |
| Revenue growth (YoY) | — | -60.55% |
| Net income (latest FY) | $-13.72M | $-204.38M |
| Operating margin | — | -504.09% |
| Net margin | — | -478.33% |
| 52-week high | $124.82 | $21.73 |
| 52-week low | $50.07 | $2.55 |
| Distance from 52-week high | -44.72% | -88.22% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +88.65% | +549.61% |
| Average volume | 151.83K | 3.11M |
| Shares outstanding | 6.78M | 197.23M |
| Employees | 22 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNPR has outperformed WVE by 39.0 percentage points over the past year.
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Wave Life Sciences
WVE stock →Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
MNPR vs WVE FAQ
Which is bigger, Monopar Therapeutics or Wave Life Sciences?
Wave Life Sciences (WVE) is larger, with a market capitalization of $504.91M compared with $467.60M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, MNPR or WVE?
MNPR returned -24.64% over the past 12 months, compared with -63.69% for WVE (price return, excluding dividends). Past performance does not predict future results.
Are Monopar Therapeutics and Wave Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.